ContentsIssue 47 • January 2022In association withWhen is a drug a device?We explore the regulatory grey area between drugs and devices and what it can mean for manufacturersIN DEPTHTackling telemedicine fraudstersCommentOmicron could energise flu testingBriefingIndustry newsMedical industry briefingCovid-19 briefingCommentOmicron variant could energise flu testingMicroLabs aims to boost Covid-19 surveillanceIoT will tackle demand on mental health servicesIn DepthWhen is a drug a device?3D printing in drug manufacturingTackling telemedicine fraudstersESG in clinical trials: key themesWinners of our Excellence AwardsIn DataInvestment themes to watchData analytics hiring on the riseNorth America’s big data hiring boomMarkets and indicesMacro-economic data05/23/2024 00:03:11
Comment
Omicron could energise flu testing